By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alnylam Pharmaceuticals 

300 Third Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-551-8200 Fax: 617-551-8101


Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease.

The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.

Key Statistics

Ownership: Public

Web Site: Alnylam Pharmaceuticals
Symbol: ALNY



Cubist Pharmaceuticals, Inc. 

Company News
Alnylam Pharmaceuticals (ALNY) Launches Alnylam Assist™, Dedicated To Providing Support To Patients, Families, And Caregivers In Certain Genetic Diseases 10/20/2014 7:52:42 AM
Alnylam Pharmaceuticals (ALNY) Presents New Clinical And Pre-Clinical Data On RNAi Therapeutics At 10th Oligonucleotide Therapeutics Society (OTS) Meeting 10/14/2014 7:30:24 AM
Alnylam Pharmaceuticals (ALNY) Reports Six-Month Clinical Data From Patisiran Phase 2 Open-Label Extension (OLE) Study In Patients With Familial Amyloidotic Polyneuropathy (FAP) 10/13/2014 11:17:35 AM
Alnylam Pharmaceuticals (ALNY) Initiates EXPLORE, A Prospective Observational Study Of Patients With Hepatic Porphyrias 10/1/2014 10:54:52 AM
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At Leerink Partners Rare Disease Roundtable 9/25/2014 9:19:19 AM
Alnylam Pharmaceuticals (ALNY) Initiates DISCOVERY, A Screening Study Examining The Prevalence Of Transthyretin (TTR) Mutations In Patients Suspected Of Having Cardiac Amyloidosis 9/24/2014 9:01:13 AM
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At 21st Annual NewsMakers In The Biotech Industry Conference 9/22/2014 1:28:28 PM
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 9/16/2014 8:56:52 AM
Alnylam Pharmaceuticals (ALNY) Strengthens Management Team With New Key Appointments 9/15/2014 10:13:09 AM
Alnylam Pharmaceuticals (ALNY) Broadens Pipeline With ALN-AGT, A Subcutaneously Administered Rnai Therapeutic Targeting Angiotensinogen (AGT) For The Treatment Of Hypertensive Disorders Of Pregnancy (HDP), Including Preeclampsia 9/12/2014 11:04:41 AM